<DOC>
	<DOCNO>NCT02296476</DOCNO>
	<brief_summary>Open-label , phase IIa , non-randomized , multicentric study single-agent OTX015 recurrent GBM ( glioblastoma Multiforme ) patient standard front-line therapy failure . The first study step ( dose escalation ) determine maximum tolerate dose ( MTD ) use standard 3+3 dose escalation enrol 3 patient per OTX015 dose level ( DL ) , additional 3 patient enrol first occurrence dose-limiting toxicity ( DLT ) . MTD assessment base tolerability observe first 28 day treatment . The second study step ( expansion cohort ) ass OTX015 efficacy measure progression-free survival rate 6 month ( PFS-6 ) recurrent GBM patient assess local investigator confirm independent central review committee . A two-stage design use step allow possibility stop trial early lack efficacy .</brief_summary>
	<brief_title>A Trial With Dose Optimization OTX015 Recurrent Glioblastoma Multiforme ( GBM ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>1 . Signed informed consent obtain prior initiation studyspecific procedure treatment . Patients register trial must treat follow participate center ; 2 . Histologically confirm diagnosis de novo glioblastoma multiforme ( World Health Organization grade IV astrocytoma ) unequivocal tumor recurrence MRI scan ( perform stable steroid dosage receive least 5 day ) follow frontline treatment surgical resection , cranial radiotherapy temozolomide ; patient undergo surgical resection part frontline therapy due anatomical location base neurosurgeon 's assessment permit confirmatory tumor biopsy perform ; 3 . At least one measurable and/or nonmeasurable lesion per Response Assessment NeuroOncology ( RANO ) criterion ( Wen et al. , 2010 ) ; 4 . Age ≥ 18 year ; 5 . Life expectancy &gt; 3 month ; 6 . Karnofsky performance status ( KPS ) ≥ 70 % ; 7 . Adequate bone marrow reserve , renal liver function : Absolute neutrophil count ≥ 1.5 x109/L , Platelet count ≥ 150 x109/L , Hemoglobin ≥ 10 g/dL , Creatinine 2 x upper limit normal ( ULN ) calculate creatinine clearance ≥ 30 mL/min ( Cockroft Gault formula MDRD formula patient age &gt; 65 year ) , Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 3 x ULN , total bilirubin ≤ ULN ; 8 . An interval ≥ 2 week since surgical resection , ≥ 4 week since chemotherapy ( ≥ 6 week nitrosoureas ) , ≥12 week since radiotherapy completion start study treatment ; patient recent tumor resection must MRI within 48 hour postsurgery ; 9 . Availability archive tumor pathology specimen ( paraffinembedded frozen block ) . 1 . Prior antineoplastic treatment recurrent disease include VEGF/VEGFR inhibitor cytotoxic agent ; 2 . Unable undergo MRI noncompatible device ; 3 . Unable swallow oral medication presence gastrointestinal disorder ( e.g . malabsorption , resection ) deem jeopardize intestinal absorption ; 4 . Persistent grade &gt; 1 clinically significant toxicity relate prior antineoplastic therapy ; 5 . History prior concomitant malignancy within 5 year study entry ( excised nonmelanoma skin cancer cure situ cervical carcinoma ) . Males concurrent control hormone dependent prostate cancer allow ; 6 . Other serious illness medical condition investigator 's opinion could hamper understand study patient , patient 's compliance study treatment , patient 's safety , interpretation study result . These include ( restrict ) existence significant neurologic psychiatric disorder impair ability obtain consent , uncontrolled infection know HIV positivity ; 7 . Concurrent enzymeinducing antiepileptic drug ( EIAED ) use ; 8 . Concurrent strong CYP3A4 interacting drug ; 9 . Participation another clinical trial treatment investigational drug within 4 week prior first study treatment administration , 5 halflives previously administer drug , whichever longer ; 10 . Pregnant breastfeeding patient , men woman childbearing potential use effective contraception study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>